David Benigson is CEO of Signal AI, a company using AI and media data to help executives cut through noise and drive actionable insights. Risk is no longer a four-letter word—it's a critical factor ...

Organizations are integrating previously disparate services to better align their offerings with the shift from fee-for-service to risk-based care through visionary, member-centric solutions. For ...

The U.S. Food and Drug Administration (FDA) recently finalized its guidance, “A Risk-Based Approach to Monitoring of Clinical Investigations” (the “2023 RBM Guidance”) which follows up on the Agency’s ...

The American Gastroenterology Association (AGA) Institute issued new clinical practice guidelines, providing evidence-based recommendations for managing hepatitis B reactivation (HBVr) in at-risk ...

Clinical trials can often take between six and seven years to complete, but that timeline isn’t always practical for the problems pharmaceutical companies are trying to solve. Additionally, six years ...

For several years now, the healthcare industry has been slowly but surely inching toward the tipping point of value-based care. While the Health Care Payment Learning & Action Network (HCPLAN) states ...

Publisher's note: This material was paid for by CCS Medical and provided by CCS Medical. The views expressed by the author are their own. This material is not part of Health Affairs Forefront; it has ...